- Home
- LXEH vs QUCY Comparison
LXEH vs QUCY Comparison
Compare LXEH & QUCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LXEH | QUCY |
|---|---|---|
| Founded | 2001 | 2008 |
| Country | China | Germany |
| Employees | N/A | 13 |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 5.9M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LXEH | QUCY |
|---|---|---|
| Price | $0.19 | $0.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 491.6K | 230.8K |
| Earning Date | 05-01-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $74.34 |
| Revenue Next Year | N/A | $171.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.40 |
| 52 Week High | $26.50 | $0.74 |
Technical Indicators
Market Signals| Indicator | LXEH | QUCY |
|---|---|---|
| Relative Strength Index (RSI) | 45.99 | 27.89 |
| Support Level | $0.18 | $0.42 |
| Resistance Level | $0.26 | $0.53 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 17.74 | 44.49 |
Price Performance
Historical ComparisonAbout LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About QUCY Mainz Biomed N.V. Ordinary Shares
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.